Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Trimarchi Thomas, holds the title of President and CFO at BridgeBio Pharma, Inc..
On 2026-11-16, the insider transacted 22,781 shares.The shares were transacted at a weighted average price of $77.36 per share, resulting in a total market-relevant value of $1.8M.
Trimarchi Thomas (President and CFO) had withheld for taxes $1.8M of $BBIO
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.